← Dashboard
Pipeline: Profile Scout Research Draft Applied

U.S. Rare Disease Biotech Investing Rises After... | PharmExec

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report
AMBER Tx General
Strategy Notes
Keyword match: +2 relevant, -0 negative signals.
Key Materials
Your Notes
Status & Deadline
Status
INELIGIBLE
Deadline
Cycle
rolling
Amount
Type
grant
URL
Apply
Update Status
Log Application
AI Pipeline
Research Programme Generate Draft
Status History
2026-08-12 OPEN → INELIGIBLE · The page is a news article about the FDA Priority Review Voucher program; no funding application, deadline, or eligibility criteria are provided.